Skip to main content

Xenon Pharmaceuticals Inc(XENE-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low41.05
Day High42.24
Open:41.81
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

TOP STORIES: Xenon Pharmaceuticals Inc

Select a category then submit the form to load news
the globe and mail
An employee at Xenon work inside the lab in Burnaby, B.C, on Friday, December 1, 2023. Tijana Martin/ The Globe and Mail
the globe and mail

Xenon awaiting critical epilepsy drug study results that could lead to FDA approval

B.C. drug developer expecting results in March after positive trial results five years ago
Tipranks
Analysts Conflicted on These Healthcare Names: Xenon (XENE), Arvinas Holding Company (ARVN) and Esperion (ESPR)
Tipranks
Xenon Pharmaceuticals Refreshes $400 Million ATM Equity Program
Tipranks
Stifel Nicolaus Reaffirms Their Buy Rating on Xenon (XENE)
Tipranks
Analysts Conflicted on These Healthcare Names: Xenon (XENE), Idexx Laboratories (IDXX) and Warby Parker (WRBY)
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Xenon (XENE), Alector (ALEC) and Caris Life Sciences, Inc. (CAI)
Tipranks
Analysts Offer Insights on Healthcare Companies: Xenon (XENE) and Caris Life Sciences, Inc. (CAI)
Tipranks
Guggenheim Remains a Buy on Xenon (XENE)
Tipranks
Xenon (XENE) Gets a Buy from Wells Fargo
Tipranks
RBC Capital Keeps Their Buy Rating on Xenon (XENE)
Tipranks
Analysts Offer Insights on Healthcare Companies: Ginkgo Bioworks Holdings (DNA) and Xenon (XENE)
Tipranks
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX) and Xenon (XENE)
Tipranks
Xenon Highlights 2025 Results and Expands Late-Stage Pipeline
GlobeNewswire
Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update
Tipranks
Analysts Offer Insights on Healthcare Companies: Xenon (XENE) and Alphatec Holdings (ATEC)
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Xenon (XENE), Hims & Hers Health (HIMS) and Merck & Company (MRK)
Tipranks
Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (DAWN) and Xenon (XENE)
Motley Fool
From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer
Motley Fool
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake
Motley Fool
Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million
Motley Fool
Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50%
Motley Fool
Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29%
Motley Fool
Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data
Motley Fool
Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress
Motley Fool
Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million
Tipranks
Analysts Conflicted on These Healthcare Names: CVS Health (CVS), Madrigal Pharmaceuticals (MDGL) and Xenon (XENE)
Tipranks
Xenon (XENE) Receives a Buy from J.P. Morgan
Tipranks
Xenon Pharmaceuticals Issues Inducement Stock Options to New Hires
GlobeNewswire
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tipranks
Xenon Sets 2026–2027 Milestone Timetable for Azetukalner and Pain Pipeline
GlobeNewswire
Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference
Tipranks
Analysts Offer Insights on Healthcare Companies: Evolus (EOLS) and Xenon (XENE)
Tipranks
Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO) and Xenon (XENE)

Profile

Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan as well as more prevalent diseases. The company offers Glybera (R), a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Xenon Pharmaceuticals Inc. is headquartered in Burnaby, Canada.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.